title: Synthesis and biological activity of 17 alpha-alkynylamide derivatives of estradiol.
abstract: Seven estradiol (E2) derivatives with an alkynylamide side chain at the 17 alpha position were synthesized starting from ethynylestradiol (EE2). The main chemical step was the coupling reaction of the acetylide ion of EE2 with carbon dioxide, glutaric anhydride or bromoalkyl ortho ester. The synthesis of these compounds is fast (3-6 steps according to the compound) and is easily achieved with good yield. Five compounds with different side chain lengths were evaluated for uterotrophic and antiuterotrophic activity in the CD-1 mouse. None of the tested compounds shows estrogenic activity in this sensitive in vivo system. At low doses (1 and 3 micrograms), a 14-57% inhibition of E2-induced uterine growth was observed while no additional inhibition was observed at the 10, 20 and 30 micrograms doses. In human breast carcinoma cells in culture, all compounds show estrogenic activity at high concentrations while only compound 39 (N-butyl,N-methyl-8-[3',17' beta-dihydroxy estra-1',3',5'(10')-trien-17' alpha-yl]-7-octynamide) possesses antiproliferative or antiestrogenic effects. No significant correlation could be demonstrated between alkynylamide side chain length and estrogenic or antiestrogenic activity. Among the compounds tested, the derivative of EE2 possessing a five-methylene (CH2) side chain (compound 39) possesses the best antiestrogenic activity (44 +/- 7% in the CD-1 mouse uterus assay at the 3 micrograms dose and 57 +/- 4% at 0.1 nM in human ZR-75-1 cancer cells in culture.
authors.affiliation: MRC Group in Molecular Endocrinology, CHUL Research Center, Quebec, Canada.
authors.forename: D
authors.initials: D
authors.lastname: Poirier
authors.forename: C
authors.initials: C
authors.lastname: Labrie
authors.forename: Y
authors.initials: Y
authors.lastname: Mérand
authors.forename: F
authors.initials: F
authors.lastname: Labrie
mesh_terms: D000818:Animals; D001943:Breast Neoplasms / Q000473:pathology; D002455:Cell Division / Q000187:drug effects; D055598:Chemical Phenomena; D002621:Chemistry; D004958:Estradiol / Q000031:analogs & derivatives* / Q000138:chemical synthesis / Q000378:metabolism / Q000494:pharmacology; D004965:Estrogen Antagonists / Q000138:chemical synthesis* / Q000378:metabolism / Q000494:pharmacology; D004997:Ethinyl Estradiol / Q000737:chemistry*; D005260:Female; D006801:Humans; D051379:Mice; D015394:Molecular Structure; D009929:Organ Size / Q000187:drug effects; D051381:Rats; D011960:Receptors, Estrogen / Q000378:metabolism; D013329:Structure-Activity Relationship; D014407:Tumor Cells, Cultured; D014599:Uterus / Q000033:anatomy & histology / Q000187:drug effects / Q000378:metabolism
chemical_list: D004965:Estrogen Antagonists; D011960:Receptors, Estrogen; C069760:N-butyl,N-methyl-8-(3',17'-dihydroxyestra-1',3',5'(10')-trien-17'-yl)-7-octynamide; D004997:Ethinyl Estradiol; D004958:Estradiol